Procalcitonin for diagnosis of infection and guide to antibiotic decisions: Past, present and future

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Schuetz, Philipp ^a   Albrich, Werner ^b   Mueller, Beat ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b University Department of Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL DECISION MAKING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; DIAGNOSTIC PROCEDURES; DRUG MONITORING; METHODOLOGY; RESPIRATORY TRACT INFECTION; SEPSIS; SURGICAL INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CALCITONIN; CLINICAL LABORATORY TECHNIQUES; DRUG MONITORING; HUMANS; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; SEPSIS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 80053173738     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-107     Document Type: Review

References (78)

1. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, . Active Bacterial Core Surveillance Program of the Emerging Infections Program Network Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924. 10.1056/NEJM200012283432603, 11136262, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.
2. Roberts Rebecca R, Hota B, Ahmad I, Scott Ii RD, Foster Susan D, Abbasi F, Schabowski S, Kampe Linda M, Ciavarella Ginevra G, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clin Infect Dis 2009, 49:1175-1184. 10.1086/605630, 19739972.
3. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011, 6(Suppl 1):S4-15.
4. Lee TH, Goldman L. Evaluation of the patient with acute chest pain. N Engl J Med 2000, 342:1187-1195. 10.1056/NEJM200004203421607, 10770985.
5. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010, 363:266-274. 10.1056/NEJMra0907731, 20592294.
6. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, Nusbaumer C, Tamm M, Christ-Crain M. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10. 10.1186/1471-2334-7-10, 1821031, 17335562.
7. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000, 181:176-180. 10.1086/315214, 10608764.
8. Christ-Crain M, Muller B. Procalcitonin in bacterial infections--hype, hope, more or less?. Swiss Med Wkly 2005, 135:451-460.
9. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007, 30:556-573. 10.1183/09031936.00166106, 17766633.
10. Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005, 146:2699-2708. 10.1210/en.2004-1424, 15761041.
11. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype?. Swiss Med Wkly 2009, 139:318-326.
12. Becker KL. Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its Precursors. J Clin Endocrinol Metab 2004, 89:1512-1525. 10.1210/jc.2002-021444, 15070906.
13. Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection 2007, 35:352-355. 10.1007/s15010-007-7065-0, 17882355.
14. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, Schuetz P. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129. 10.1378/chest.10954, 20299634.
15. van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, van Dissel JT. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010, 14:R206. 10.1186/cc9328, 2934199, 21083886.
16. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93. 10.1164/rccm.200512-1922OC, 16603606.
17. Schuetz P, Christ-Crain M, Albrich W, Zimmerli W, Mueller B. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence 2010, 1:88-92. 10.4161/viru.1.2.10488, 21178422.
18. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Resp J 2011, 37:384-392.
19. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355. 10.1183/09031936.00054507, 17959641.
20. Huang D, Weissfeld L, Kellum J, Yealy D, Kong L, Martino M, Angus D. Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia. Ann Emerg Med 2008, 52:48-58.e2. 10.1016/j.annemergmed.2008.01.003, 2775454, 18342993.
21. Haeuptle J, Zaborsky R, Fiumefreddo R, Trampuz A, Steffen I, Frei R, Christ-Crain M, Muller B, Schuetz P. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009, 28:55-60. 10.1007/s10096-008-0592-5, 18677519.
22. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602. 10.1097/01.CCM.0000239116.01855.61, 16915118.
23. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010, 8:575-587. 10.1586/eri.10.25, 20455686.
24. Nylen ES, Muller B, Becker KL, Snyder RH. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003, 36:823-824. 10.1086/368088, 12627371.
25. Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, Ponzio A, Bonfa A, Hubl W, Demant T, Kulpmann WR, Buchholz J, Schumann G. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 2004, 42:440-449. 10.1515/CCLM.2004.077, 15147156.
26. Pecile P, Miorin E, Romanello C, Falleti E, Valent F, Giacomuzzi F, Tenore A. Procalcitonin: a marker of severity of acute pyelonephritis among children. Pediatrics 2004, 114:e249-254. 10.1542/peds.114.2.e249, 15286264.
27. Knudsen JB, Fuursted K, Petersen E, Wierup P, Molgaard H, Poulsen SH, Egeblad H. Procalcitonin in 759 patients clinically suspected of infective endocarditis. Am J Med 2010, 123:1121-1127. 10.1016/j.amjmed.2010.07.018, 20870199.
28. Mueller C, Huber R, Laifer G, Mueller B, Buerkle G, Perruchoud AP. Procalcitonin and the early diagnosis of infective endocarditis. Circulation 2004, 109:1707-1710. 10.1161/01.CIR.0000126281.52345.52, 15066945.
29. Kafetzis DA, Velissariou IM, Nikolaides P, Sklavos M, Maktabi M, Spyridis G, Kafetzis DD, Androulakakis E. Procalcitonin as a predictor of severe appendicitis in children. Eur J Clin Microbiol Infect Dis 24:484-487.
30. Sand M, Trullen XV, Bechara FG, Pala XF, Sand D, Landgrafe G, Mann B. A prospective bicenter study investigating the diagnostic value of procalcitonin in patients with acute appendicitis. Eur Surg Res 2009, 43:291-297. 10.1159/000232939, 2790741, 19672084.
31. Anielski R, Kusnierz-Cabala B, Szafraniec K. An evaluation of the utility of additional tests in the preoperative diagnostics of acute appendicitis. Langenbecks Arch Surg 2010, 395:1061-1068. 10.1007/s00423-009-0565-x, 19924436.
32. Markogiannakis H, Memos N, Messaris E, Dardamanis D, Larentzakis A, Papanikolaou D, Zografos GC. Manouras: Predictive value of procalcitonin for bowel ischemia and necrosis in bowel obstruction. Surgery 2011, 149:394-403. 10.1016/j.surg.2010.08.007, 20869092.
33. Gurda-Duda A, Kusnierz-Cabala B, Nowak W, Naskalski JW, Kulig J. Assessment of the prognostic value of certain acute-phase proteins and procalcitonin in the prognosis of acute pancreatitis. Pancreas 2008, 37:449-453. 10.1097/MPA.0b013e3181706d67, 18953261.
34. Brunkhorst FM, Eberhard OK, Brunkhorst R. Early identification of biliary pancreatitis with procalcitonin. Am J Gastroenterol 1998, 93:1191-1192.
35. Bihari D. Monitoring procalcitonin is of value in acute pancreatitis. BMJ 2004, 329:232. 487782, 15271847.
36. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009, 146:72-81. 10.1016/j.surg.2009.02.013, 19541012.
37. Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol 2008, 26:453-456.
38. Butbul-Aviel Y, Koren A, Halevy R, Sakran W. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care 2005, 21:828-832. 10.1097/01.pec.0000190226.12610.24, 16340758.
39. Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, Wu A, Lawlor C, Dalton H. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediat Crit Care Med 2005, 6:129-135.
40. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008, 36:396-407. 10.1007/s15010-008-7374-y, 18759057.
41. Koivula I, S HMLI, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, Juutilainen A. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis 2011, 43:471-478. 10.3109/00365548.2011.554855, 21299364.
42. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, Mantovani A. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002, 72:643-649.
43. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008, 34:518-522. 10.1007/s00134-007-0955-x, 2244699, 18080111.
44. Timper K, Grisouard J, Radimerski T, Dembinski K, Peterli R, Haring A, Frey DM, Zulewski H, Keller U, Muller B, Christ-Crain M. Glucose-dependent insulinotropic polypeptide (GIP) induces calcitonin gene-related peptide (CGRP)-I and procalcitonin (Pro-CT) production in human adipocytes. J Clin Endocrinol Metab 2011, 96:E297-303. 10.1210/jc.2010-1324, 21106708.
45. Radimerski TM, Grisouard J, Timper K, Zulewski H, Christ-Crain M, Keller U, Muller B. Role of calcium in lipopolysaccharide-induced calcitonin gene expression in human adipocytes. Innate Immun 2010,
46. Linscheid P. In Vitro and in Vivo Calcitonin I Gene Expression in Parenchymal Cells: A Novel Product of Human Adipose Tissue. Endocrinology 2003, 144:5578-5584. 10.1210/en.2003-0854, 12960010.
47. Schuetz P, Christ-Crain M, Huber AR, Muller B. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. Clin Biochem 2010, 43:341-344. 10.1016/j.clinbiochem.2009.08.029, 19747473.
48. Hubl W, Krassler J, Zingler C, Pertschy A, Hentschel J, Gerhards-Reich C, Mack M, Demant T. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 2003, 49:319-327.
49. de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M. Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. Clin Chem 2009, 55:1043-1044. 10.1373/clinchem.2008.117655, 19264851.
50. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607. 10.1016/S0140-6736(04)15591-8, 14987884.
51. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131:9-19. 10.1378/chest.06-1500, 17218551.
52. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, . ProHOSP Study Group Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066. 10.1001/jama.2009.1297, 19738090, ProHOSP Study Group.
53. Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, Storgaard M, Sodemann M. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect 2009, 15:481-487. 10.1111/j.1469-0691.2009.02709.x, 19416298.
54. Long W, Deng XQ, Tang JG, Xie J, Zhang YC, Zhang Y, Gao YY, Lu G. [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient]. Zhonghua Nei Ke Za Zhi 2009, 48:216-219.
55. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin-guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Respirology 2011, 16:819-824. 10.1111/j.1440-1843.2011.01978.x, 21507143.
56. Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, Brutsche M, Huber AR, Muller B. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 2010, 29:269-277. 10.1007/s10096-009-0851-0, 20039090.
57. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002, 359:1648-1654. 10.1016/S0140-6736(02)08597-5, 12020525.
58. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010, 36:601-607. 10.1183/09031936.00163309, 20185423.
59. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, Bucher HC, Muller B. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005, 6:34. 10.1186/1471-2296-6-34, 1190167, 16107222.
60. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008, 168:2000-2007. discussion 2007-2008, 10.1001/archinte.168.18.2000, 18852401.
61. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505.
62. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, . PRORATA trial group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA trial group.
63. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Timm M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375. 10.1183/09031936.00053209, 19797133.
64. Hochreiter M, Köhler T, Schweiger A, Keck F, Bein B, von Spiegel T, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009, 13:R83. 10.1186/cc7903, 2717450, 19493352.
65. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009, 394:221-226. 10.1007/s00423-008-0432-1, 19034493.
66. Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, Suttor N, Welte T. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65. 10.1186/1465-9921-10-65, 2714042, 19594893.
67. Kruger S, Ewig S, Kunde J, Hartmann O, Marre R, Suttorp N, Welte T. Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010, 411:1929-1934. 10.1016/j.cca.2010.08.004, 20699094.
68. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34:1996-2003. 10.1097/01.CCM.0000226413.54364.36, 16715031.
69. Hunziker S, Hugle T, Schuchardt K, Groeschl I, Schuetz P, Mueller B, Dick W, Eriksson U, Trampuz A. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am 92:138-148.
70. Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006, 10(5):R145. 10.1186/cc5067, 1751067, 17038199.
71. Schuetz P, Affolter B, Hunziker S, Winterhalder C, Fischer M, Balestra GM, Hunziker P, Marsch S. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest 2010, 40:376-381. 10.1111/j.1365-2362.2010.02259.x, 20192974.
72. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, . for the The Procalcitonin And Survival Study (PASS) Study Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011, for the The Procalcitonin And Survival Study (PASS) Study Group.
73. Martinot M, Sordet C, Soubrier M, Puechal X, Saraux A, Liote F, Guggenbuhl P, Legre V, Jaulhac B, Maillefert JF, Zeisel M, Coumaros G, Sibilia J. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol 2005, 23:303-310.
74. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 2011, 135:182-189. 10.1309/AJCP1MFYINQLECV2, 21228358.
75. Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez JL, Lebon P, Bohuon C. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997, 24:1240-1242. 10.1086/513633, 9195090.
76. Marc E, Menager C, Moulin F, Stos B, Chalumeau M, Guerin S, Lebon P, Brunet F, Raymond J, Gendrel D. [Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak]. Arch Pediatr 2002, 9:358-364. 10.1016/S0929-693X(01)00793-X, 11998420.
77. Mary R, Veinberg F, Couderc R. [Acute meningitidis, acute phase proteins and procalcitonin]. Ann Biol Clin 2003, 61:127-137.
78. Hunziker S, Hugle T, Schuchardt K, Groeschl I, Schuetz P, Mueller B, Dick W, Eriksson U, Trampuz A. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am 2010, 92:138-148. 10.2106/JBJS.H.01600, 20048106.